We are live on ! Find out more
ITOS

iTeos Therapeutics
ITOS

Delisted

ITOS was delisted on the 28th of August, 2025.

Back to rankings

143 hedge funds and large institutions have $699M invested in iTeos Therapeutics in 2022 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 63 increasing their positions, 34 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

85% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 34

1.36% less ownership

Funds ownership: 104.5% → 103.14% (-1.4%)

6% less funds holding

Funds holding: 152 → 143 (-9)

9% less capital invested

Capital invested by funds: $768M → $699M (-$69M)

32% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 28

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
143
Holders Change
-9
Holders Change %
-5.92%
% of All Funds
2.46%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
19
Increased
63
Reduced
34
Closed
28
Calls
$201K
Puts
–
Net Calls
+$201K
Net Calls Change
-$3.97M

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$14M
2
BlackRock
BlackRock
New York
+$13.7M
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$10.7M
4
Millennium Management
Millennium Management
New York
+$9.53M
5
Ameriprise
Ameriprise
Minnesota
+$4.69M

Top Sellers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
-$16.9M
2
Deutsche Bank
Deutsche Bank
Germany
-$13.4M
3
AllianceBernstein
AllianceBernstein
Tennessee
-$12.9M
4
State Street
State Street
Massachusetts
-$8.53M
5
EC
EcoR1 Capital
California
-$5.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
26
Citigroup
New York
$5.61M +$3.88M +168,551 +134%
Acadian Asset Management
27
Acadian Asset Management
Massachusetts
$4.98M -$672K -29,173 -10%
BCM
28
Bridgeway Capital Management
Texas
$4.64M +$2.96M +128,500 +112%
Northern Trust
29
Northern Trust
Illinois
$4.61M +$196K +8,528 +4%
American Century Companies
30
American Century Companies
Missouri
$4.24M +$1.32M +57,252 +35%
Barclays
31
Barclays
United Kingdom
$4.23M +$4.43M +192,220 +649%
Axa
32
Axa
France
$4.2M +$1.27M +55,266 +33%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$4.08M +$778K +33,780 +19%
IHAM
34
Integral Health Asset Management
New York
$3.71M +$886K +38,447 +25%
Charles Schwab
35
Charles Schwab
California
$3.39M +$629K +27,288 +18%
Principal Financial Group
36
Principal Financial Group
Iowa
$3.22M +$32.2K +1,399 +0.8%
Federated Hermes
37
Federated Hermes
Pennsylvania
$3.1M -$558K -24,243 -13%
BBA
38
Baker Bros. Advisors
New York
$2.86M – – –
Prudential Financial
39
Prudential Financial
New Jersey
$2.76M +$745K +32,355 +29%
Rafferty Asset Management
40
Rafferty Asset Management
New York
$2.4M +$616K +26,733 +27%
Wellington Management Group
41
Wellington Management Group
Massachusetts
$2.33M +$409K +17,738 +17%
Massachusetts Financial Services
42
Massachusetts Financial Services
Massachusetts
$2.31M -$25.5K -1,106 -0.9%
Man Group
43
Man Group
United Kingdom
$2.22M +$2.69M +116,579 New
Voloridge Investment Management
44
Voloridge Investment Management
Florida
$1.94M +$392K +17,016 +20%
N
45
Nuveen
North Carolina
$1.91M -$2.98M -129,173 -56%
DCM
46
DAFNA Capital Management
California
$1.86M -$178K -7,738 -7%
SEI Investments
47
SEI Investments
Pennsylvania
$1.84M +$469K +20,378 +27%
Janus Henderson Group
48
Janus Henderson Group
United Kingdom
$1.84M +$1.1M +47,850 +99%
Los Angeles Capital Management
49
Los Angeles Capital Management
California
$1.67M -$852K -36,971 -30%
Two Sigma Advisers
50
Two Sigma Advisers
New York
$1.64M -$1.59M -69,000 -44%
1
2
3 4 5

ITOS Hedge Fund Activity: Q3 2022 in Review

143 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q3 2022, worth a combined $699M — down 9% from $768M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of ITOS and 19 opened new positions — a net loss of 9 holders — while 34 trimmed existing stakes and 63 added.

The largest buyer was Citadel Advisors, adding an estimated $14M. The largest seller was Rubric Capital Management (New York), exiting entirely with an estimated $16.9M sold.

  • 143 institutional investors held iTeos Therapeutics (ITOS) as of Q3 2022, down from 152 in Q2 2022.
  • Funds reported $699M of iTeos Therapeutics stock for Q3 2022, down 9% quarter-over-quarter.
  • 19 funds opened new iTeos Therapeutics positions in Q3 2022 and 28 closed out, a net change of -9 holders.
  • The largest iTeos Therapeutics buyer in Q3 2022 was Citadel Advisors, an estimated $14M added.
  • The largest iTeos Therapeutics seller in Q3 2022 was Rubric Capital Management (New York), an estimated $16.9M sold.

Based on aggregated 13F filings for Q3 2022.